Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01288430 · ClinicalTrials.gov registry record · Phase 1
A Study of DS-2248 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01288430 is a Phase 1 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 60 participants.
The verdict
NCT01288430, a Phase 1 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This phase 1 clinical trial is intended to understand the safety and tolerability of a new anticancer drug in subjects with advanced solid tumors. The patients who qualify for the study will receive a once daily dose of the drug taken by mouth and will undergo several tests to measure the drug in the blood and to understand the safety, tolerability and any effect of the drug on the tumor. The antitumor effect of the drug is not known in human.
Interventions
- DRUG DS-2248
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-03-29 |
| Est. Completion | 2014-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01288430
The ClinicalTrials.gov registry entry for NCT01288430 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DS-2248 is the first listed.
NCT01288430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01288430 about?
NCT01288430 is a clinical study titled "A Study of DS-2248 in Participants With Advanced Solid Tumors". This phase 1 clinical trial is intended to understand the safety and tolerability of a new anticancer drug in subjects with advanced solid tumors. The patients who qualify for the study will receive a once daily dose of the drug taken by mouth and will undergo several tests to measure the drug in th...
What is the current status of trial NCT01288430?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2011-03-29. Estimated completion is 2014-02-13.
What interventions are being tested in trial NCT01288430?
The interventions under investigation include: DS-2248 (DRUG).
Who is sponsoring clinical trial NCT01288430?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.